W C Coetzee1, J P Apffelstaedt2, T Zeeman3, M Du Plessis4. 1. Department of General Surgery, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa. wernercarel@gmail.com. 2. Department of General Surgery, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa. 3. , Bellville, South Africa. 4. , Tokai, Cape Town, South Africa.
Abstract
INTRODUCTION: Different outcomes in breast cancer have been reported for low and high socio-economic groups. We present data quantifying disparities between South African public and private patients. METHODS: Records of 240 consecutive patients treated in 2008 in a public versus 97 patients in a private health facility were reviewed for demographic and oncologic data. RESULTS: The average of patients was 56.2 versus 51.9 years (p = 0.032). Stage at presentation was 0 in 0.83 versus 25.8%, I in 4.5 versus 15.5%, II in 41.3 versus 37.1%, III in 37.1 versus 18.6% and IV in 16.3 versus 3.1% public versus private patients. Seventy-three percent of patients were symptomatic versus 57.7%. Of patients with stage 0-III disease, 17.9 versus 20% had simple tumour excision and 7.5 versus 14%, oncoplastic tumour excision. The mastectomy rate was similar (52 vs. 60%), but immediate reconstruction was performed in 10 versus 63%. Public patients were less likely to have radiotherapy. The pathology was similar, 27.2 versus 20, 54 versus 52, 87 versus 61% of patients with stage I, II and III disease, respectively, had chemotherapy. Hormonal therapy for premenopausal patients in private was a LHRH agonist in 9.3%, ovarian ablation/BSO in 11.7% of public patients; biologicals were given in 7.2 versus 0% of patients. Overall survival for public versus private was 66 versus 80% (p < 0.001) months. Better per stage survival of private patients 100 versus 100, 72.7 versus 93.3, 84.8 versus 88.9, 57.3 versus 77.8 and 33 versus 33% for stages 0, I, II, III and IV, did not reach statistical significance. CONCLUSION: The greatest impact on outcome was stage at presentation, but more aggressive therapy for each stage resulted in a trend to better outcome for private patients.
INTRODUCTION: Different outcomes in breast cancer have been reported for low and high socio-economic groups. We present data quantifying disparities between South African public and private patients. METHODS: Records of 240 consecutive patients treated in 2008 in a public versus 97 patients in a private health facility were reviewed for demographic and oncologic data. RESULTS: The average of patients was 56.2 versus 51.9 years (p = 0.032). Stage at presentation was 0 in 0.83 versus 25.8%, I in 4.5 versus 15.5%, II in 41.3 versus 37.1%, III in 37.1 versus 18.6% and IV in 16.3 versus 3.1% public versus private patients. Seventy-three percent of patients were symptomatic versus 57.7%. Of patients with stage 0-III disease, 17.9 versus 20% had simple tumour excision and 7.5 versus 14%, oncoplastic tumour excision. The mastectomy rate was similar (52 vs. 60%), but immediate reconstruction was performed in 10 versus 63%. Public patients were less likely to have radiotherapy. The pathology was similar, 27.2 versus 20, 54 versus 52, 87 versus 61% of patients with stage I, II and III disease, respectively, had chemotherapy. Hormonal therapy for premenopausal patients in private was a LHRH agonist in 9.3%, ovarian ablation/BSO in 11.7% of public patients; biologicals were given in 7.2 versus 0% of patients. Overall survival for public versus private was 66 versus 80% (p < 0.001) months. Better per stage survival of private patients 100 versus 100, 72.7 versus 93.3, 84.8 versus 88.9, 57.3 versus 77.8 and 33 versus 33% for stages 0, I, II, III and IV, did not reach statistical significance. CONCLUSION: The greatest impact on outcome was stage at presentation, but more aggressive therapy for each stage resulted in a trend to better outcome for private patients.
Authors: Nakul Saxena; Mikael Hartman; Nirmala Bhoo-Pathy; Jennifer N W Lim; Tar-Ching Aw; Philip Iau; Nur Aishah Taib; Soo-Chin Lee; Cheng-Har Yip; Helena M Verkooijen Journal: World J Surg Date: 2012-12 Impact factor: 3.352
Authors: Pedro E R Liedke; Dianne M Finkelstein; Jackie Szymonifka; Carlos H Barrios; Yanin Chavarri-Guerra; José Bines; Cláudia Vasconcelos; Sérgio D Simon; Paul E Goss Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-10-28 Impact factor: 4.254
Authors: Claudia P Orlas; Juan Pablo Herrera-Escobar; Cheryl K Zogg; José J Serna; Juan J Meléndez; Alexandra Gómez; Diana Martínez; Michael W Parra; Alberto F García; Fernando Rosso; Luis Fernando Pino; Adolfo Gonzalez; Carlos A Ordoñez Journal: World J Surg Date: 2020-06 Impact factor: 3.352
Authors: Daniel S O'Neil; Wenlong Carl Chen; Oluwatosin Ayeni; Sarah Nietz; Ines Buccimazza; Urishka Singh; Sharon Čačala; Laura Stopforth; Maureen Joffe; Katherine D Crew; Judith S Jacobson; Alfred I Neugut; Paul Ruff; Herbert Cubasch Journal: J Glob Oncol Date: 2019-11
Authors: Sarah Nietz; Daniel S O'Neil; Oluwatosin Ayeni; Wenlong Carl Chen; Maureen Joffe; Judith S Jacobson; Alfred I Neugut; Paul Ruff; Witness Mapanga; Ines Buccimazza; Urishka Singh; Sharon Čačala; Laura Stopforth; Boitumelo Phakathi; Tobias Chirwa; Herbert Cubasch Journal: Breast Cancer Res Treat Date: 2020-09-01 Impact factor: 4.872